Insight Molecular Diagnostics (IMDX) Equity Ratio (2015 - 2026)

Insight Molecular Diagnostics has disclosed Equity Ratio across 12 years of filings, most recently posting 0.26 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.26, down 256.22% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.26 (down 256.22% YoY), and the FY2025 annual result was 1.22, down 249.16% from the prior year.
• Equity Ratio came in at 0.26 for Q1 2026 at Insight Molecular Diagnostics, up from 1.22 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.5 in Q2 2023 to a low of 1.22 in Q4 2025.
• The 5-year median for Equity Ratio is 0.27 (2023), against an average of 0.13.
• Across the five-year window, Equity Ratio gained 17.63% in 2023 and tumbled 256.22% in 2026, its largest moves.
• Insight Molecular Diagnostics' Equity Ratio stood at 0.34 in 2022, then dropped by 20.23% to 0.27 in 2023, then slumped by 228.02% to 0.35 in 2024, then plunged by 249.16% to 1.22 in 2025, then soared by 78.35% to 0.26 in 2026.
• The last three Equity Ratio figures came in at 0.26 (Q1 2026), 1.22 (Q4 2025), and 0.21 (Q3 2025), per Business Quant data.